This is a community-generated profile. If you work at Replimune Group, to claim it.

Replimune Group develops next-generation oncolytic immunotherapies for cancer treatment201-500 Employees
- Recently fundedRaised funding in the past six months
Replimune Group Funding
$150M
11 round
Replimune Group has secured funding across 1 rounds, totaling in an amount of $150M. Their most recent funding was raised on August 10, 2026.
Funding Rounds
S
$150000000